Back to top

Neurocrine initiates Phase 1 study of NBIP-‘1968

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘1...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Neurocrine Biosciences, Inc. (NBIX)